Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: Response to 1 year of treatment and 1 year of withdrawal

Journal of Neurosurgery

Volumn 106, Issue 4, 2007, Pages 614-620

  Slevin, John T ^a,b   Gash, Don M ^a   Smith, Charles D ^a   Gerhardt, Greg A ^a   Kryscio, Richard ^a   Chebrolu, Himachandra ^a   Walton, Ashley ^a   Wagner, Renee ^a   Young, A Byron ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b LEXINGTON VA MEDICAL CENTER   (United States)

Author keywords

Clinical trial; Efficacy; Glial cell line derived neurotrophic factor; Parkinson disease; Putamen

Indexed keywords

GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA;

ADULT; AGED; ARTICLE; BRAIN TOXICITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLIA CELL; HUMAN; INFECTION; MALE; MOTOR PERFORMANCE; NUCLEAR MAGNETIC RESONANCE IMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; QUALITY OF LIFE; RISK FACTOR;

AGED; ANTIPARKINSON AGENTS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; INFUSION PUMPS, IMPLANTABLE; MALE; MIDDLE AGED; MOTOR ACTIVITY; PARKINSON DISEASE; PUTAMEN; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 34047220707     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2007.106.4.614     Document Type: Article

References (22)

1. Ai Y, Carter N, Zhang Z, Gerhardt GA, Gash DM: Cerebellar histopathological analysis in normal and parkinsonian rhesus monkeys following chronic intracerebral infusion of GDNF. Soc Neurosci Abstracts, 2005 (Abstract)
2. Beck KD, Valverde J, Alexi T, Poulsen K, Moffat B, Vandlen RA, et al: Mesencephalic dopaminergic neurons protected by GDNF from axotomy-induced degeneration in the adult brain. Nature 373:339-341, 1995
3. Chebrolu H, Slevin JT, Gash DA, Gerhardt GA, Young B, Given CA, et al: MRI volumetric and intensity analysis of the cerebellum in Parkinson's disease patients infused with glial-derived neurotrophic factor (GDNF). Exp Neurol 198:450-456, 2006
4. Defer GL, Widner H, Marie RM, Remy P, Levivier M: Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 14:572-584, 1999
5. Ericson C, Georgievska B, Lundberg C: Ex vivo gene delivery of GDNF using primary astrocytes transduced with a lentiviral vector provides neuroprotection in a rat model of Parkinson's disease. Eur J Neurosci 22:2755-2764, 2005
6. Francis GS, Rice GP, Alsop JC, PRISMS Study Group: Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 65:48-55, 2005
7. Gash DM, Zhang Z, Ai Y, Grondin R, Coffey R, Gerhardt GA: Trophic factor distribution predicts functional recovery in parkinsonian monkeys. Ann Neurol 58:224-233, 2005
8. Gash DM, Zhang Z, Ovadia A, Cass WA, Yi A, Simmerman L, et al: Functional recovery in parkinsonian monkeys treated with GDNF. Nature 380:252-255, 1996
9. Gill SS, Patel NK, Hotton GR, O'Sullivan K, McCarter R, Bunnage M, et al: Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 9:589-595, 2003
10. Holm S: A simple sequentially rejective multiple test procedure. Scand J Statist 6:65-70, 1979
11. Hutchinson M, Gurney S, Newson R: GDNF in Parkinson disease: An object lesson in the tyranny of type II. J Neurosci Methods, 2006 (Epub ahead of print July 27, 2006)
12. Kappos L, Clanet M, Sandberg-Wollheim M, Radue EW, Hartung HP, Hohlfeld R, et al: Neutralizing antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 65:40-47, 2005
13. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, et al: Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 59:459-466, 2006
14. Love S, Plaha P, Patel NK, Hotton GR, Brooks DJ, Gill SS: Glial cell line-derived neurotrophic factor induces neuronal sprouting in human brain. Nat Med 11:703-704, 2005
15. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, et al: Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 60:69-73, 2003
16. Patel NK, Bunnage M, Plaha P, Svendsen CN, Heywood P, Gill SS: Intraputamenal infusion of glial cell line-derived neurotrophic factor in PD: a two-year outcome study. Ann Neurol 57:298-302, 2005
17. Peck P: Amgen decision to halt GDNF clinical trials and withdraw the drug triggers protest from researchers and patients. Neurology Today 3:4, 7, 24, 2005
18. Sajadi A, Bensadoun JC, Schneider BL, Lo Bianco C, Aebischer P: Transient striatal delivery of GDNF via encapsulated cells leads to sustained behavioral improvement in a bilateral model of Parkinson disease. Neurobiol Dis 22:119-129, 2005
19. Salvatore MF, Ai Y, Fischer B, Zhang AM, Grondin RC, Zhang Z, et al: Point source concentration of GDNF may explain failure of phase II clinical trial. Exp Neurol 202:497-505, 2006
20. Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW: Crossroads in GDNF therapy for Parkinson's disease. Mov Disord 21:136-141, 2006
21. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B: Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 102:216-222, 2005
22. Tomac A, Lindqvist E, Lin LF, Ogren SO, Young D, Hoffer BJ, et al: Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo. Nature 373:335-339, 1995